

cel claim 5 upon the allowance of the other claims in the application.


The rejection of claims 1-4 under the second paragraph of 35 U.S.C. 112 has been obviated by the amendments to the claims. In particular, the claims no longer include the language "characterized", and "characterized in that". Moreover, the claims now recite having or containing in order to render the claims more definite. Furthermore, claims 1 and 3 have been amended so as to clearly point out the claimed structural arrangement of the compounds. The criticism of claims 3 and 4 as being incomplete has been overcome since claims 3 and 4 now recite the presence of a pharmaceutical carrier and also recite the use of the compositions for the preventive treatment or treatment of arterial thrombosis. The amount of the active ingredient is recited in functional language as being sufficient for anticoagulation activity.

Claims 3 and 4 were rejected under the second paragraph of 35 U.S.C. 112 as being substantial duplicates of claims 1 and 2. This rejection of claims 3 and 4 has been overcome by the above amendments to claims 3 and 4 wherein the presence of a carrier and the amount of active ingredient is recited in functional language.

The references cited by the Examiner have merely been cited to show the status of the art and none of the claims have been rejected thereover. Accordingly, it is respectfully requested that favorable action be given this application.

Respectfully submitted,

DATE: 3-6-81


Burton A. Amernick
Reg. No. 24,852

331-7111

POLLOCK, VANDÉ SANDE & PRIDDY
1990 M STREET, N. W.
POST OFFICE BOX 19088
WASHINGTON, D. C. 20036